31433153, 2013 [39] R
the present invention solves these problems by providing BPC peptide salts and a pharmaceutical or diagnostic composition comprising a pharmaceutically or diagnostically effective amount of the salts of BPC peptides said peptides being constituted of 8 to 15 amino acids, wherein the anion of the salt is a negatively charged peptide comprising 8 amino acid residues having the general formula (I) wherein Xaa is a neutral aliphatic amino acid residue, in particular Ala, bAla, Leu, Ile, Gly, Val, Nle or Nva, Yaa is a basic amino acid residue, in particular Lys, Arg, Orn or His and Zaa is an acidic amino acid residue, in particular Glu, Asp, Aad or Apm and wherein the cation of the salt is the cation of an inorganic or organic nontoxic and pharmaceutically acceptable base
Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity
We are finalizing to add descriptive headings to redesignated paragraphs 425.512(b)(4) and (b)(5)
Wongwanakul et al., 2023)
Comment: One commenter suggested CMS consult with ophthalmologists about how they have integrated the transfer of care modifiers into their clinical practice to see if there is guidance that could be developed to apply across specialties based on their practice of using these modifiers more frequently than other physicians